Editorial comment on:“Systemic treatment of hepatocellular carcinoma:an EASL position paper”  

作　　者：Daniel H.Ahn Tanios Bekaii-Saab 

机构地区：[1]Division of Hematology/Medical Oncology,Mayo Clinic Arizona,Phoenix,AZ,USA

出　　处：《Hepatobiliary Surgery and Nutrition》2022年第1期112-114,共3页肝胆外科与营养（英文）

摘　　要：Hepatocellular carcinoma is the most common cancer of the liver and worldwide,the sixth most common cancer and the third most common cause of cancer related deaths(1).The management and treatment of this disease requires a multi-disciplinary approach,which is observed in the staging and classification.In 1999,the development of the Barcelona Clinic Liver Cancer(BCLC)classification system helped to guide the appropriate treatments based on stage.While patients with stage A disease would be candidates for locoregional treatment including surgical resection,liver transplantation or liver directed therapy,treatment in patients with intermediate(B)or advanced(C)stage disease would be palliative,where the recommendation would for systemic therapy.

关 键 词：classification. treatment CANCER 

分 类 号：R73[医药卫生—肿瘤]